MLV

MLV Initiates Yuma Energy With Buy

MLV Upgrades Rose Rock Midstream To Buy

UPDATE: MLV Initiates Coverage On Agios Pharmaceuticals

MLV Upgrades Rose Rock Midstream To Buy

UPDATE: MLV Initiates Coverage On Agios Pharmaceuticals

UPDATE: MLV & Co. Upgrades Starwood Hotels & Resorts Worldwide

UPDATE: MLV Downgrades LaSalle Hotel Properties

UPDATE: MLV & Co. Upgrades Starwood Hotels & Resorts Worldwide

UPDATE: MLV Downgrades LaSalle Hotel Properties

UPDATE: MLV Initiates Pluristem Therapeutics at Buy on Unique Cell Therapy Platform

UPDATE: MLV Downgrades CapLease to Hold, Raises PT Following American Realty Capital Properties Merger Announcement

MLV Recent News

UPDATE: MLV Initiates Starwood Property Trust at Buy with $25.50 on Balance Sheet Strength

UPDATE: MLV Initiates NorthStar Realty Finance at Buy with PT of $6.50 on Valuation

UPDATE: MLV Initiates Buy, $6 PT on Resource Capital Corporation on Return Profile

UPDATE: MLV Initiates Cytokinetics with Buy, $4 PT

MLV Starts Coverage on Crimson Exploration, Gives Buy Rating and $5.50 PT

MLV Starts Coverage on Crimson Exploration, Gives Buy Rating and $5.50 PT

UPDATE: MLV Raises Transcept Pharmaceuticals' PT

UPDATE: MLV Raises Target to $10 on Curis

MLV Maintains Buy, $4 Target on Zalicus Post Settlement

MLV Reiterates Buy, $15 PT on Alnylam Pharmaceuticals

UPDATE: MLV Initiates Buy, $6 PT on Avanir Pharmaceutical

UPDATE: MLV Raises Price Target on Inhibitex to $26

UPDATE: MLV & Co Initiates Buy, $4 Target on Zalicus

UPDATE: MLV Raising Price Target on Cerus Corp.

UPDATE: MLV Raising Price Target on Inhibitex

MLV Maintains Buy on Double Eagle Petroleum

MLV Initiates Coverage of Sunesis Pharmaceuticals with a Buy Rating

MLV Initiates Coverage On Agenus

UPDATE: MLV Raises PT on Aastrom Biosciences to $7.50

MLV Maintains Buy on ArQule

UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50

MLV Maintains Buy on Genomic Health

MLV Provides Color on Affymax